Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), is a liver disease worldwide without approved therapeutic drugs. Anti-inflammatory and hepatoprotective drug bicyclol and multi-pharmacological active drug berberine, respectively, have sh...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hu Li, Nan-Nan Liu, Jian-Rui Li, Biao Dong, Mei-Xi Wang, Jia-Li Tan, Xue-Kai Wang, Jing Jiang, Lei Lei, Hong-Ying Li, Han Sun, Jian-Dong Jiang, Zong-Gen Peng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-02-01
Edice:	Frontiers in Pharmacology
Témata:	nonalcoholic fatty liver disease bicyclol berberine combination lipid metabolism gut microbiota
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.843872/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!